

Peritonitis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P2BA12E095DEN.html>

Date: May 2020

Pages: 45

Price: US\$ 2,000.00 (Single User License)

ID: P2BA12E095DEN

Abstracts

Peritonitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis – Pipeline Review, H1 2020, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritonitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II

and Preclinical stages are 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Peritonitis - Overview
- Peritonitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Peritonitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peritonitis - Companies Involved in Therapeutics Development
- Arrevis Inc
- Ayvis Research Inc
- GlaxoSmithKline Plc
- Hunan Sanqing Pharmaceutical Co Ltd
- Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
- Nosopharm SAS
- Oncodesign SA
- Reponex Pharmaceuticals Aps
- SynAct Pharma AB
- Peritonitis - Drug Profiles
- AP-1189 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ARV-1502 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aspoxicillin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

AVR-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceforanide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOSO-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ODS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NLRP3 for Inflammatory Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-3025 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peritonitis - Dormant Projects

Peritonitis - Product Development Milestones

Featured News & Press Releases

Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Peritonitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Peritonitis - Pipeline by Arrevus Inc, H1 2020
Peritonitis - Pipeline by Ayuvis Research Inc, H1 2020
Peritonitis - Pipeline by GlaxoSmithKline Plc, H1 2020
Peritonitis - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020
Peritonitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H1 2020
Peritonitis - Pipeline by Nosopharm SAS, H1 2020
Peritonitis - Pipeline by Oncodesign SA, H1 2020
Peritonitis - Pipeline by Reponex Pharmaceuticals Aps, H1 2020
Peritonitis - Pipeline by SynAct Pharma AB, H1 2020
Peritonitis - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peritonitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Arrevus Inc
Ayuvis Research Inc
GlaxoSmithKline Plc
Hunan Sanqing Pharmaceutical Co Ltd
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Nosopharm SAS
Oncodesign SA
Reponex Pharmaceuticals Aps
SynAct Pharma AB

I would like to order

Product name: Peritonitis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P2BA12E095DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P2BA12E095DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970